{"id":14108,"date":"2020-08-24T11:30:01","date_gmt":"2020-08-24T09:30:01","guid":{"rendered":"https:\/\/idibell.cat\/?p=14108"},"modified":"2020-09-01T10:46:20","modified_gmt":"2020-09-01T08:46:20","slug":"identifiquen-una-nova-combinacio-de-farmacs-per-tractar-rabdomiosarcoma-un-tumor-altament-agressiu-en-nens","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2020\/08\/identifiquen-una-nova-combinacio-de-farmacs-per-tractar-rabdomiosarcoma-un-tumor-altament-agressiu-en-nens\/","title":{"rendered":"Identifiquen una nova combinaci\u00f3 de f\u00e0rmacs per tractar rabdomiosarcoma, un tumor altament agressiu en nens"},"content":{"rendered":"<p>El <a href=\"https:\/\/idibell.cat\/recerca\/area-de-cancer\/programa-de-mecanismes-molleculars-i-terapia-experimental-en-oncologia-oncobell\/quimioresistencia-i-xenografts-ortotopics\/\" target=\"_blank\" rel=\"noopener noreferrer\">grup de quimioresist\u00e8ncia<\/a> del Programa ProCURE de l\u2019IDIBELL i l&#8217;ICO, sota la direcci\u00f3 de l\u2019investigador Alberto Villanueva, ha col\u00b7laborat en un estudi liderat per l\u2019Institut de Bioenginyeria de Catalunya (<a href=\"http:\/\/www.ibecbarcelona.eu\/ca\/\" target=\"_blank\" rel=\"noopener noreferrer\">IBEC<\/a>) en el que han investigat l\u2019\u00fas seq\u00fcencial de combinacions de dosis baixes d\u2019agents quimioterap\u00e8utics amb mim\u00e8tics BH3 per augmentar l\u2019efic\u00e0cia dels tractaments actuals del rabdomiosarcoma, un tumor pedi\u00e0tric molt agressiu. Aquesta nova estrat\u00e8gia, alhora que millora la resposta antitumoral, disminueix la toxicitat indu\u00efda per la ter\u00e0pia i la protecci\u00f3 antiapopt\u00f2tica evitant la resist\u00e8ncia als tractaments. En la investigaci\u00f3, s\u2019han combinat tant estudis in vitro en l\u00ednies cel\u00b7lulars com in vivo en orthoxenografts, o PDOX derivats de pacients.<\/p>\n<p>L&#8217;equip d\u2019Alberto Villanueva ha traslladat la seva \u00e0mplia experi\u00e8ncia en la generaci\u00f3 de models tumorals ortot\u00f2pics en ratolins, \u00e9s a dir, fragments de tumors humans implantats en els ratolins en el mateix \u00f2rgan d&#8217;origen, de tumors d&#8217;adults al terreny pedi\u00e0tric amb l&#8217;objectiu d\u2019ajudar a millorar el seu tractament. Aix\u00ed, en els \u00faltims anys i en col\u00b7laboraci\u00f3, majorit\u00e0riament, amb el Servei d&#8217;Oncologia Pedi\u00e0trica de l&#8217;Hospital Vall d&#8217;Hebron han generat un important banc d&#8217;aquest tipus de models tumorals pedi\u00e0trics. Un d&#8217;ells \u00e9s el que s&#8217;ha utilitzat per a poder avan\u00e7ar en la millora del tractament del rabdomiosarcoma presentat en aquest treball. Aix\u00ed mateix, en aquest estudi a m\u00e9s tamb\u00e9 ha participat la unitat de Oncol\u00f2gica Pedi\u00e0trica de l&#8217;Hospital de Sant Joan de Deu, aix\u00ed com l&#8217;spin-off Xenopat S.L com a part de la seva acci\u00f3 social corporativa.<\/p>\n<p>El rabdomiosarcoma, el sarcoma de teixits tous m\u00e9s freq\u00fcent en pacients pedi\u00e0trics, \u00e9s un tipus de tumor altament agressiu i que no sol tenir bon pron\u00f2stic, especialment en pacients refractaris o amb recaiguda. Actualment l\u2019estrat\u00e8gia terap\u00e8utica inclou quimioter\u00e0pia, radioter\u00e0pia i cirurgia per\u00f2 la baixa taxa de superviv\u00e8ncia en pacients d\u2019alt risc, aix\u00ed com les elevades toxicitats derivades del tractament i la manca de biomarcadors evidencien la necessitat de noves estrat\u00e8gies terap\u00e8utiques.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>El grup de quimioresist\u00e8ncia del Programa PROCURE de l\u2019IDIBELL i l&#8217;ICO, liderat per Alberto Villanueva, ha traslladat la seva experi\u00e8ncia en la generaci\u00f3 de models ortot\u00f2pics de ratolins en pacients adults al terreny pedi\u00e0tric.<\/p>\n","protected":false},"author":8,"featured_media":14109,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[346],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-10 11:39:44","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/14108"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=14108"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/14108\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/14109"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=14108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=14108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=14108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}